Loading organizations...
Resistomap provides advanced environmental surveillance of antimicrobial resistance (AMR) by analyzing environmental DNA (eDNA) from various sources. The company leverages high-throughput quantitative PCR (HT-qPCR) technology to precisely quantify hundreds of antibiotic resistance genes, including those at low abundance. This molecular analysis is integrated with the cloud-based Resistomap Platform, which offers interactive tools for data interpretation, including an Antibiotic Resistance Gene Index, reduction tracking, and risk assessment for comprehensive insights.
The company was launched in 2018 by Dr. Windi Muziasari and William Nurmi. Their foundational insight stemmed from the critical need for accessible and straightforward methods to monitor antibiotic resistance in the environment, recognizing its compounding complexity due to pollution and broader health challenges. Resistomap was formed to combine microbiology and data science expertise to address this global health threat.
Resistomap serves a diverse clientele including sectors such as water and wastewater treatment, agriculture, public health, aquaculture, livestock, and food safety, in addition to supporting research initiatives. The company's vision is to lead globally in environmental antibiotic resistance monitoring, guided by a One Health approach. This philosophy emphasizes the interconnectedness of human, animal, and environmental health, aiming to contribute to global safety and sustainability by transforming complex genetic data into actionable insights for effective AMR risk management.
Resistomap has raised $2.0M across 1 funding round.
Resistomap has raised $2.0M in total across 1 funding round.
Resistomap has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in November 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2023 | $2M Seed | Ananda Impact Ventures | 24Haymarket, Gaingels | Announced |
Resistomap is a technology company specializing in environmental monitoring of antimicrobial resistance (AMR) using advanced molecular genetics and data science. It offers a comprehensive biosecurity intelligence platform that leverages environmental DNA (eDNA) and high-throughput quantitative PCR (HT-qPCR) technology to track and analyze antibiotic resistance genes in various environmental samples. Resistomap serves sectors such as water and wastewater treatment, public health, aquaculture, livestock, food safety, and research, addressing the critical global challenge of AMR by enabling early detection and informed action to mitigate resistance spread[1][2][3].
Founded in 2018 by Windi Muziasari and William Nurmi in Helsinki, Finland, Resistomap emerged from the need to revolutionize how AMR is monitored in the environment. The founders combined expertise in molecular biology and environmental science to develop a platform that integrates sampling, genetic analysis, and data visualization. Early traction included building one of the most extensive environmental AMR databases and securing investment in 2023 to scale their impact globally[1][4].
Resistomap rides the critical global trend of combating antimicrobial resistance, a growing public health threat exacerbated by environmental reservoirs of resistance genes. The timing is crucial as regulatory bodies and industries increasingly demand robust AMR surveillance to safeguard medical treatment efficacy and environmental health. Market forces such as rising awareness of environmental biosecurity, advances in molecular diagnostics, and the integration of AI and data science in life sciences favor Resistomap’s growth. By providing actionable intelligence, Resistomap influences the broader ecosystem by enabling stakeholders to identify hotspots, monitor trends, and implement targeted interventions to curb AMR spread[1][5].
Looking ahead, Resistomap is poised to expand its platform capabilities, incorporating more AI-driven analytics and broadening its global footprint. Trends shaping its journey include increased regulatory focus on environmental AMR, growing demand for sustainable biosecurity solutions, and technological advances in eDNA and molecular diagnostics. As Resistomap scales, its influence may extend beyond monitoring to predictive modeling and real-time AMR management, reinforcing its role as a key player in global health and environmental protection. This evolution ties back to its mission of transforming AMR monitoring to save lives and protect ecosystems worldwide[1][4][5].
Resistomap has raised $2.0M in total across 1 funding round.
Resistomap's investors include Ananda Impact Ventures, 24Haymarket, Gaingels.
